Journal of Medicinal Chemistry · 1999 · 93 citations · 10 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyOrganic ChemistryStructure-activity RelationshipsAllosteric ModulationAllosteric Modulator DesignAllosteric RegulationLead Compound DesignLigand BindingReceptor PharmacologyAdenosine Receptor ModulationAgonist ActivityAllosteric AgonismAllosteric AgonistsAllosteric DrugsBinding Affinity EnhancementBiological Evaluation ReportEnhancers
Novel allosteric enhancers of agonist binding to the rat adenosine A(1) receptor are described. The lead compound for the new series was PD 81,723 ((2-amino-4, 5-dimethyl-3-thienyl)[3-(trifluoromethyl)phenyl]methanone), a compound previously reported by Bruns and co-workers (Mol. Pharmacol. 1990, 38, 950-958). The 4,5-dimethyl group and the benzoyl moiety were targets for further modifications, leading to series of 4, 5-dialkyl (12a-g), of tetrahydrobenzo (12h-u), and of tetrahydropyridine (13a-g) derivatives. A number of compounds, in particular 12b, 12e, 12j, 12n, and 12u, proved superior to PD 81,723. Their EC(50) values for enhancing the binding of the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine to the receptor were lower, and/or their antagonistic activity on the adenosine A(1) receptor was shown to be diminished.
10
Measurement of protein using bicinchoninic acid
Pam Smith, Randall I. Krohn, Greg T. Hermanson et al. · Analytical Biochemistry · 1985 · 18.4K citations
Jean-Claude Rousselle, O. Massot, Muriel Delepierre et al. · Journal of Biological Chemistry · 1996 · 64 citations · Full text
Medicine, Neuroscience, Pharmacology +17